The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in
improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant
human research participants, and this is further improved by combination therapy with
tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic
patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a
placebo.